Edward Pershing - 22 Aug 2025 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Signature
/s/ Edward Pershing
Issuer symbol
PVCT
Transactions as of
22 Aug 2025
Transactions value $
-$100,000
Form type
4
Filing time
22 Aug 2025, 14:38:25 UTC
Previous filing
12 Aug 2025
Next filing
27 Aug 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Pershing Edward CEO, Director 800 S. GAY STREET,, SUITE 1610, KNOXVILLE /s/ Edward Pershing 22 Aug 2025 0001689739

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT 8% Unsecured Convertible Promissory Note Options Exercise -$100K $1.27M 22 Aug 2025 Series D-1 Convertible Preferred Stock 37.8K $2.86 Direct F3, F4
transaction PVCT Series D-1 Convertible Preferred Stock Options Exercise $0 +37.8K +1.63% $0.00 2.35M 22 Aug 2025 Common Stock 378K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F2 The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
F3 The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2024 Note") at any time while the 2024 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2024 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2024 Note. The 2024 Note was issued pursuant to the Issuer's 2024 Financing.
F4 On August 22, 2025, the 2024 Note was converted into 37,760 shares of Series D-1 Preferred Stock.